Bertrand

Aquyre develops 2 minute biopsy assessment products, in the operating room for Cancer Diagnosis and Next Generation Sequencing. Aquyre captures data from fresh live biopsies and analysis it into images and diagnosis.

CEO
Leadership
- Expanded the team from 15 to 50 members, encompassing all functions across the U.S. and France. Designed and implemented operational processes.
- Strategically relocated the company from France to Boston, USA.

Revenue generation
- Built a top-tier sales team, creating robust reporting tools (Salesforce)
- Sold systems globally for medical and research applications, penetrating key markets in Europe, the U.S., Japan, and the Middle East.
- Leveraged early robotics adopters and high-volume centers for commercial success.
- Developed and executed sales and marketing strategies with KOLs, focusing on key conferences and high-potential customers.

Board and investors management
- Managed Board of Directors and Investor relations, fostering transparency and strong relationships.
- Orchestrated quarterly meetings, ensured corporate governance compliance, and added shareholder value.
- Conducted equity flip, transferring French investor to U.S. parent company.

Financing: $50 M including $25M series A
- Secured funding from seed to series B, including equity and debt financing.
- Identified and negotiated with investors across EU, U.S., and Asia

Strategy development and implementation
- Developed and implemented a market entry strategy with lung biopsies: dramatically
improved % of successful procedures from 60 to 95-100%.
- Designed a new business model emphasizing recurring subscriptions, data, cloud, and AI, demonstrating potential to double revenue and triple company valuation.

Business development
- Established partnerships with industry leaders and top U.S. teaching hospitals: Johns Hopkins, UPMC Pittsburgh, University of Chicago, Boston University, John Muir.
- Selected Key Opinion Leaders to promote Aquyre.

Alliances and partnership
- Established relationships with leading medical imaging and robotics companies in the U.S., E.U., and Asia, securing equity investments and joint research deals.

Product development
- Translated market needs into a user-friendly, automated product.
- Developed an integrated solution from hardware (microscopy) to data (AI analysis) and cloud-based remote analysis.

Manufacturing
- Secured multi-year contracts with key chip vendors during the COVID-19 crisis.
- Transitioned from handmade prototypes to series production and established manufacturing procedures.
Quality insurance
- Supervised the implementation of Quality Assurance strategy, best practices, and documentation.